These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 34402338

  • 1. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
    Wei LC, Chan HY.
    Am J Drug Alcohol Abuse; 2021 Sep 03; 47(5):590-598. PubMed ID: 34402338
    [Abstract] [Full Text] [Related]

  • 2. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh F, Nubukpo P, Brousse G.
    Drug Alcohol Depend; 2021 Mar 01; 220():108492. PubMed ID: 33482572
    [Abstract] [Full Text] [Related]

  • 3. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
    Manhapra A, Stefanovics E, Rosenheck R.
    Subst Abus; 2020 Mar 01; 41(1):110-120. PubMed ID: 31403914
    [Abstract] [Full Text] [Related]

  • 4. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI, Burt R, Thiede H, Glick SN.
    Subst Abus; 2018 Jan 02; 39(1):83-88. PubMed ID: 28796591
    [Abstract] [Full Text] [Related]

  • 5. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW, Buntin MB, Martin PR, Scott TA, Dupont W, Richards M, Cooper WO.
    Subst Abus; 2019 Jan 02; 40(3):356-362. PubMed ID: 29949454
    [Abstract] [Full Text] [Related]

  • 6. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
    Mocanu V, Bozinoff N, Wood E, Jutras-Aswad D, Le Foll B, Lim R, Cheol Choi J, Yin Mok W, Eugenia Socias M, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse.
    Drug Alcohol Depend; 2023 Jul 01; 248():109932. PubMed ID: 37224674
    [Abstract] [Full Text] [Related]

  • 7. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
    Brothers TD, Fraser J, MacAdam E, Morgan B, Webster D.
    Drug Alcohol Rev; 2022 Feb 01; 41(2):430-434. PubMed ID: 34347327
    [Abstract] [Full Text] [Related]

  • 8. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J, Saunders J.
    BMC Psychiatry; 2022 Jul 30; 22(1):516. PubMed ID: 35908052
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A, Quinones L, Rosenheck R.
    Drug Alcohol Depend; 2016 Mar 01; 160():82-9. PubMed ID: 26804898
    [Abstract] [Full Text] [Related]

  • 10. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA.
    Drug Alcohol Depend; 2016 Mar 01; 160():112-8. PubMed ID: 26796596
    [Abstract] [Full Text] [Related]

  • 11. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL.
    Addiction; 2021 Jan 01; 116(1):83-93. PubMed ID: 32428276
    [Abstract] [Full Text] [Related]

  • 12. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, Garment AR, Giftos J, Lee JD.
    Addict Sci Clin Pract; 2019 Oct 01; 14(1):37. PubMed ID: 31570100
    [Abstract] [Full Text] [Related]

  • 13. Factors associated with buprenorphine versus methadone use in pregnancy.
    Krans EE, Bogen D, Richardson G, Park SY, Dunn SL, Day N.
    Subst Abus; 2016 Oct 01; 37(4):550-557. PubMed ID: 26914546
    [Abstract] [Full Text] [Related]

  • 14. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L, Iversen J, Wand H, Maher L.
    Addiction; 2021 Mar 01; 116(3):525-535. PubMed ID: 32557931
    [Abstract] [Full Text] [Related]

  • 15. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T, McCormack D, Bozinoff N, Tadrous M, Antoniou T, Munro C, Campbell T, Paterson JM, Mamdani M, Sproule B.
    Addiction; 2022 Jul 01; 117(7):1972-1981. PubMed ID: 35257434
    [Abstract] [Full Text] [Related]

  • 16. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK, Robertson AG, Jones H, Powell BJ, Silberman P, Domino ME.
    Health Serv Res; 2020 Jun 01; 55(3):383-392. PubMed ID: 32166761
    [Abstract] [Full Text] [Related]

  • 17. Barriers to retention in medications for opioid use disorder treatment in real-world practice.
    Villamil VI, Underwood N, Cremer LJ, Rooks-Peck CR, Jiang X, Guy GP.
    J Subst Use Addict Treat; 2024 May 01; 160():209310. PubMed ID: 38331319
    [Abstract] [Full Text] [Related]

  • 18. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M, Groß G.
    Am J Drug Alcohol Abuse; 2021 Sep 03; 47(5):599-604. PubMed ID: 34407703
    [Abstract] [Full Text] [Related]

  • 19. Multimodal assessment of sleep in men and women during treatment for opioid use disorder.
    Finan PH, Mun CJ, Epstein DH, Kowalczyk WJ, Phillips KA, Agage D, Smith MT, Preston KL.
    Drug Alcohol Depend; 2020 Feb 01; 207():107698. PubMed ID: 31816489
    [Abstract] [Full Text] [Related]

  • 20. History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020.
    Hallowell BD, Weidele HR, Daly M, Chambers LC, Scagos RP, Gargano L, McDonald J.
    Am J Public Health; 2021 Sep 01; 111(9):1600-1603. PubMed ID: 34410818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.